Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]
Discontinued
Reference number: GID-TA10356
The Department for Health and Social Care has asked NICE to conduct an appraisal of enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies.
However, the company have advised that the European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies. Therefore, NICE has decided to suspend this appraisal from its work program.
As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.